Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence - Top-Institutions - MDSpire

Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence

  • By

  • Jiaju Li

  • Yiwei Lai

  • Chao Jiang

  • Mingxiao Li

  • Zejun Yang

  • Manlin Zhao

  • Xiaodong Peng

  • Sitong Li

  • Qifan Li

  • Jiawei Chen

  • Zhen Wang

  • Suhui Zhang

  • Changsheng Ma

  • Jianzeng Dong

  • January 29, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Cardiovascular Genetics
    • Epidemiology

  • #2

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Cardiology
    • Genomic Medicine
    • Translational Research

  • #3

    University of Oxford
    University of Oxford

    Oxford, Oxfordshire

    Key Differentiators

    • Cardiovascular Medicine
    • Genetic Epidemiology
    • Population Health

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Heart Rhythm Disorders
    • Clinical Research

  • #5

    Stanford University
    Stanford University

    Stanford, CA

    Key Differentiators

    • Cardiovascular Medicine
    • Genomic Medicine
    • Precision Health

Original Source(s)

Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence

  • by Jiaju Li, Yiwei Lai, Chao Jiang, Mingxiao Li, Zejun Yang, Manlin Zhao, Xiaodong Peng, Sitong Li, Qifan Li, Jiawei Chen, Zhen Wang, Suhui Zhang, Changsheng Ma, Jianzeng Dong

  • January 29, 2025

Related Content

Outcomes following coronary artery bypass grafting with temporary left ventricular assist device support

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes